Advertisement


Krishnansu S. Tewari, MD, on Gynecologic Cancers: Expert Perspective on Major Data

ASCO 2026

Advertisement

Krishnansu S. Tewari, MD, of the University of California, Irvine, provides commentary on research presented in the oral abstract and rapid oral abstract sessions for gynecologic cancer, focusing on this year’s major trial data in endometrial, cervical, and ovarian cancers. 



Related Videos

Breast Cancer
Genomics/Genetics

Gerneiva Parkinson, MD, on Time on Systemic Therapy for Patients With HR-Positive Breast Cancer and a Pathogenic Variant

Gerneiva Parkinson, MD, of Stanford Cancer Institute, discusses time on treatment for systemic therapies among women with hormone receptor (HR)-positive breast cancer and a pathogenic variant in BRCA1, BRCA2, or PALB2 (Abstract 1096). 

Hepatobiliary Cancer

Ghassan K. Abou-Alfa, MD, PhD, FASCO, on Unresectable Embolization-Eligible HCC: Efficacy and Safety Data From EMERALD-3

Ghassan K. Abou-Alfa, MD, PhD, FASCO, of Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, presents efficacy and safety data from the randomized phase III EMERALD-3 trial, which evaluated tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization in patients with unresectable embolization-eligible hepatocellular carcinoma (LBA4000).

Skin Cancer

Shailender Bhatia, MD, on Adjuvant Avelumab in Patients With Metastatic Merkel Cell Carcinoma

Shailender Bhatia, MD, of the University of Washington and Fred Hutchinson Cancer Center, presents data from the phase III ADAM trial, a multicenter, randomized, double-blinded, placebo-controlled study of the anti–PD-L1 antibody avelumab in patients with Merkel cell carcinoma and lymph node metastases (Abstract LBA9504).

Skin Cancer

Hannah L. Kenny, MD, and Joseph M. Curry, MD, on BCC of the Head and Neck: Neoadjuvant Cemiplimab

Hannah L. Kenny, MD, and Joseph M. Curry, MD, both of Thomas Jefferson University Hospital, discuss results of a phase II trial of neoadjuvant cemiplimab-rwlc in patients with hedgehog inhibitor–naive basal cell carcinoma (BCC) of the head and neck (Abstract 9515). 

Lymphoma
Leukemia

Supriya Gupta, MD, on Investigational CAR T-Cell Therapy in Relapsed or Refractory NHL and CLL

Supriya Gupta, MD, of the University of Minnesota, presents data on azercabtagene zapreleucel, an investigational anti-CD19 allogeneic chimeric antigen receptor (CAR) T-cell therapy, in combination with low-dose interleukin-2 in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Abstract 7012). 

Advertisement

Advertisement




Advertisement